Pellegrino lists relative success rates of submissions to the FDA
Analysts understand the likelihood of success ties directly to a discount rate in valuing early-stage IP. With that in mind, Mike Pellegrino shared with BVR some FDA statistics that readers will find sobering.
Drugs targeting this disease group Experience this success rate
arthritis 20.4%
central nervous system 14.5%
cardiovascular 17.5%
gastrointestinal 20.0%
immunology 15.4%
infectious disease 28.1%
The new edition to Mike Pellegrino’s Guide to Intellectual Property Valuation is discussed here.